-
-
-
A NEW LONG-ACTING INHALED MUSCARINIC ANTAGONIST (LAMA) has been approved for treating chronic obstructive pulmonary disease (COPD).
-
A retrospective analysis of a large HMO population in Israel showed that persistent use of a statin medication over the 8-year period of analysis lowered the risk of cancer, particularly hematopoietic cancers by 31%.
-
-
Within a few years after the initiation of diagnostic X-rays, toxic effects were noted, including increased risk for skin cancer, leukemia, dermatitis, and cataracts. In this early period, doses of X-ray, especially from fluoroscopy, were high. Protective devices for patients as well as persons occupationally exposed to diagnostic radiation demonstrably reduced such adverse consequences.
-
In a prospective study of nearly 5000 postmenopausal women, it was determined that it would take 16.8 years to develop osteoporosis in 10% of women with normal bone mineral density. The authors conclude that repeat screening in women without new risk factors can be delayed for at least 15 years.
-
The authors concluded that systematically obtaining family history identifies more subjects with high CV risk who may benefit from more aggressive preventive interventions.
-
Vitamin D deficiency is associated with a significant risk of cardiovascular disease and reduced survival. Vitamin D supplementation improved survival, especially in patients with documented deficiency.
-
A new selective phosphodiesterase type 5 (PDE5) inhibitor has been approved for treating erectile dysfunction (ED). Avanafil was developed by Mitsubishi Tanabe Pharma Corporation in Japan and is manufactured in Japan and marketed by Vivus, Inc., as Stendra.
